Antibody Based Therapy in Coronary Artery Disease and Heart Failure

Fiedler, Lorna R.

doi:10.17140/hroj-4-140

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monoclonal antibodies against PI have been developed to modulate protein function and showed promise in different animal models of venous thrombosis, pulmonary embolism (PE), and ischemic stroke. 125 126 127 128 129 130 131 132 133 134 135 136 137 A monoclonal antibody against PI that interferes with the formation of PAP complexes has been shown to increase the effectiveness of tPA-mediated clot lysis. 133 Another monoclonal antibody against PI has demonstrated synergistic interactions with plasminogen activators and enhanced fibrinolysis by increasing the potency of streptokinase, t-PA, and urokinase (by 20, 27, and 80-fold, respectively).…”

Section: Targeted Plasmin Inhibitor Modification As Thrombolytic Therapymentioning

confidence: 99%

Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target

Alsayejh

Kietsiriroje

Almutairi

et al. 2022

TH Open

View full text Add to dashboard Cite

The vascular obstructive thrombus is composed of a mesh of fibrin fibres with blood cells trapped in these networks. Enhanced fibrin clot formation and/or suppression of fibrinolysis are associated with increased risk of vascular occlusive events. Inhibitors of coagulation factors and activators of plasminogen have been clinically used to limit fibrin network formation and enhance lysis. While these agents are effective at reducing vascular occlusion, they carry a significant risk of bleeding complications. Fibrin clot lysis, essential for normal haemostasis, is controlled by a number of factors including incorporation of anti-fibrinolytic proteins into the clot. Plasmin inhibitor (PI), a key anti-fibrinolytic protein, is cross-linked into fibrin networks with higher concentrations of PI documented in fibrin clots and plasma from high vascular risk individuals. This review is focused on exploring PI as a target for the prevention and treatment of vascular occlusive disease. We first discuss the relationship between PI structure and anti-fibrinolytic activity, followed by describing the function of the protein in normal physiology and role in pathological vascular thrombosis. Subsequently, we describe in detail the potential use of PI as a therapeutic target, including the array of methods employed for modulation of protein activity. Effective and safe inhibition of PI may prove to be an alternative and specific way to reduce vascular thrombotic events while keeping bleeding risk to a minimum.

show abstract

Section: Targeted Plasmin Inhibitor Modification As Thrombolytic Therapymentioning

confidence: 99%

Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target

Alsayejh

Kietsiriroje

Almutairi

et al. 2022

TH Open

View full text Add to dashboard Cite

show abstract

“…Also, there are multiple ongoing clinical trials about using monoclonal antibodies in CAD, but the outcomes will be available in the next few years [ 27 ].…”

Section: Role Of Inflammation In Myocardial Infarctionmentioning

confidence: 99%

Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome

Battisha

Sawalha

Madoukh

et al. 2021

CCR

View full text Add to dashboard Cite

: Systemic Mastocytosis (SM) is a disorder of excessive mast cell infiltration in multiple organ tissues. Atherosclerosis is a major risk factor for developing acute coronary syndrome [1]. In addition to lipid accumulation in the arterial wall, inflammation plays an important role in the pathogenesis of plaque rupture and activating the thrombosis cascade [2]. The Mast cells contribution to plaque destabilization has been well established in multiple animal and human studies [3]. In a recent study, SM has been proven to be associated with a higher incidence of acute coronary syndrome even with lower plasma lipids level [4]. The study showed that 20% of patients with SM had cardiovascular events compared to only 6% in the control group with adjustment to all cardiac risk factors. Here, we present a case of acute myocardial infarction in a patient with SM with limited risk factors other than age.

show abstract